Magnetic resonance imaging (MRI) is a radiation-free, non-invasive, preci
se, and safe medical imaging modality. By utilizing a strong magnetic fiel
d, MRI can detect the small signal from the protons in the human body aft
er the excitation by radiofrequency waves. MRI offers multi-angle scannin
g and high-contrast imaging, improving diagnostic accuracy. However, M
RI images are susceptible to motion artifacts caused by subject movemen
t or physiological motion during scans. Diffusion-weighted MRI, in particu
lar, is highly sensitive to even slight subject motion or positional changes
due to respiration or heartbeat, leading to significant image artifacts whic
h can hinder the image interpretation and clinical diagnosis.
Current methods to mitigate motion artifacts in MRI include the navigator
echo method and the multi-channel signal correction. The navigator echo
method requires the modification of pulse sequence to acquire additional
signals for the correction of phase error due to subject motion. Multi-chan
nel signal correction requires a phase array coil for multi-channel data acq
uisition to correct the motion artifact. However, the present invention offe
rs a method that does not require modifying existing MRI pulse sequence
s and is not limited by MRI hardware. If subject motion happens during sc
ans, inconsistent phase errors occur in each data acquisition. The present i
nvention utilizes an iterative algorithm to compensate the phase errors caused by subject motion with automated segmentation of MRI images. Thi
s method can automatic correct motion artifacts in MRI images without m
odifying existing sequences or being limited by hardware. It provides mor
e accurate and precise medical images for clinical use.
法人
One Model Fit All: Revolutionary One-Stop Shop System for Predicting Co ronary Stenosis without Normal Database in Myocardial Perfusion Imagin g
①The potential of Fukuoka Prefecture’s semiconductor industry ②High Quality Audio Device Series MUSES ③Optical Touchless Sensor"
Development of novel cannabinoid CB1receptor antagonists with high oral absorption and no central adverse effects for the treatment of cardiovascular diseases
Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine
Technology maturity:Experiment stage
Exhibiting purpose:Display of scientific results
Trading preferences:Negotiate by self
Coming soon!